Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809631 | 0.88 | MAPK1 (0.50) | MAPK1CHRNA7KMT2AMEN1SLC6A2 | |
| SCHEMBL8993057 | 0.83 | LTA4H (0.43) | IDO1LTA4HTAAR1 | |
| SCHEMBL16388357 | 0.82 | CALM1 (0.48) | KMT2AMEN1LTA4H | |
| SCHEMBL2633867 | 0.79 | MAPK1 (0.47) | MAPK1CHRNA7KMT2AMEN1SLC6A2 | |
| SCHEMBL7473813 | 0.78 | CCNB2 (0.35) | MAPK1KMT2AMEN1 | |
| SCHEMBL6792498 | 0.77 | MAPK1 (0.42) | MAPK1CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9778597 | 0.77 | MAOB (0.51) | DRD2LTA4HHTR2A | |
| SCHEMBL9451016 | 0.76 | MEN1 (0.44) | MAPK1KMT2AMEN1 | |
| SCHEMBL3560743 | 0.74 | MAPK1 (0.51) | MAPK1 | |
| SCHEMBL3297545 | 0.74 | MAPK1 (0.44) | MAPK1CHRNA7KMT2AMEN1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | MAPK1 3412/4885CHRNA7 1735/4885KMT2A 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.